TY - JOUR
T1 - Performance of the 2017 EULAR/ACR Classification Criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups
T2 - a scoping review
AU - Saygin, Didem
AU - Glaubitz, Stefanie
AU - Zeng, Rachel
AU - Bottai, Matteo
AU - de Visser, Marianne
AU - Dimachkie, Mazen M.
AU - Fiorentino, David
AU - Gerhardson, Ingrid
AU - Kuwana, Masataka
AU - Miller, Frederick W.
AU - Needham, Merrilee
AU - Rider, Lisa G.
AU - Salem, Yasser
AU - Schlüter, Silke
AU - Shinjo, Samuel K.
AU - Wang, Guochun
AU - Werth, Victoria P.
AU - Aggarwal, Rohit
AU - Lundberg, Ingrid E.
PY - 2024/2/1
Y1 - 2024/2/1
N2 - The 2017 EULAR/ACR classification criteria for adult/juvenile idiopathic inflammatory myopathies (IIM) were established using a data-driven approach by an international group of myositis experts to allow classification of IIM and its major subtypes. Since their publication, the performance of the criteria has been tested in multiple cohorts worldwide and significant limitations have been identified. Moreover, the understanding and classification of IIM have evolved since 2017. This scoping review was undertaken as part of a large international project to revise the EULAR/ACR criteria and aims to i) summarise the evidence from the current literature on the performance characteristics of the 2017 EULAR/ACR classification criteria in various cohorts and IIM subtypes, and ii) delineate the factors that need to be considered in the revision of the classification criteria. A systematic search of Medline (via PubMed), Cumulative Index to Nursing and Allied Health Literature, and conference abstract archives was conducted independently by three investigators for studies on the EULAR/ACR criteria published between October 2017 and January 2023. This scoping review of 19 articles and 13 abstracts revealed overall good performance characteristics of the EULAR/ACR criteria for IIM, yet deficiencies in lack of inclusion of certain IIM subtypes, such as immune mediated necrotising myopathy, amyopathic dermatomyositis, antisynthetase syndrome and overlap myositis. Published modifications that may improve the performance characteristics of the criteria for classification of IIM subtypes were also summarised. The results of this review suggest that a revision of the EULAR/ACR criteria is warranted.
AB - The 2017 EULAR/ACR classification criteria for adult/juvenile idiopathic inflammatory myopathies (IIM) were established using a data-driven approach by an international group of myositis experts to allow classification of IIM and its major subtypes. Since their publication, the performance of the criteria has been tested in multiple cohorts worldwide and significant limitations have been identified. Moreover, the understanding and classification of IIM have evolved since 2017. This scoping review was undertaken as part of a large international project to revise the EULAR/ACR criteria and aims to i) summarise the evidence from the current literature on the performance characteristics of the 2017 EULAR/ACR classification criteria in various cohorts and IIM subtypes, and ii) delineate the factors that need to be considered in the revision of the classification criteria. A systematic search of Medline (via PubMed), Cumulative Index to Nursing and Allied Health Literature, and conference abstract archives was conducted independently by three investigators for studies on the EULAR/ACR criteria published between October 2017 and January 2023. This scoping review of 19 articles and 13 abstracts revealed overall good performance characteristics of the EULAR/ACR criteria for IIM, yet deficiencies in lack of inclusion of certain IIM subtypes, such as immune mediated necrotising myopathy, amyopathic dermatomyositis, antisynthetase syndrome and overlap myositis. Published modifications that may improve the performance characteristics of the criteria for classification of IIM subtypes were also summarised. The results of this review suggest that a revision of the EULAR/ACR criteria is warranted.
UR - http://www.scopus.com/inward/record.url?scp=85187960396&partnerID=8YFLogxK
U2 - 10.55563/clinexprheumatol/vuc5py
DO - 10.55563/clinexprheumatol/vuc5py
M3 - Review article
C2 - 38436279
SN - 0392-856X
VL - 42
SP - 403
EP - 412
JO - Clinical and experimental rheumatology
JF - Clinical and experimental rheumatology
IS - 2
ER -